“The company’s decision to close operations in Rockland County is a direct result of patent expiration of one of Novartis’s key medications, Diovan. As patent rights expire on once highly lucrative drugs, generic competition increases, leading to an excess of manufacturing capacity globally. The move to leave Ramapo is in no way reflective of local tax rates, quality of life issues or any other matter.
“I have been assured the decision was taken to ensure the company’s future competitiveness in the worldwide pharmaceutical market. Rockland County will continue to compete globally by enhancing a climate that fosters new economic growth.
“In the meantime, the County is working aggressively with Novartis and the Rockland Economic Development Corporation to help displaced workers and find a buyer for the site, including repositioning the existing structures for potential users.”